PONATINIB [15 MG; CÁP/COMP] PONATINIB [15 MG; CÁP/COMP]
GOLIMUMAB [50 MG/0.5 ML; SOL INJ; CANETA/SERINGA] GOLIMUMAB [50 MG/0.5 ML; SOL INJ; CANETA/SERINGA]
Antineoplastické a imunomodulačné činidlá pre potreby FNsP. Bevacizumab con inf 1x4 ml/100 mg (liek.inj.skl.) 65 neregistrovaná očná indikácia Pertuzumab con inf 1x420 mg (liek.inj.skl.) 40 Pertuzumab and trastuzumab sol inj 1x15 ml/1200 mg/600 mg (liek.inj.skl.) 5 Pertuzumab and trastuzumab sol inj 1x10 ml/600 mg/600 mg (liek.inj.skl.) 120 Trastuzumab sol inj …
INTERFERÃO BETA-1A [6 MUI; 0,5 ML; IM; CANETA] INTERFERÃO BETA-1A [6 MUI; 0,5 ML; IM; CANETA]
IBRUTINIB [560 MG; CÁP/COMP] IBRUTINIB [560 MG; CÁP/COMP]
DURVALUMAB [50 MG/ ML; 10 ML; FRS] DURVALUMAB [50 MG/ ML; 10 ML; FRS]
IBRUTINIB [560 MG; CÁP/COMP] IBRUTINIB [560 MG; CÁP/COMP]
PONATINIB [15 MG; CÁP/COMP] PONATINIB [15 MG; CÁP/COMP]
NINTEDANIB [100MG; CÁPS] NINTEDANIB [100MG; CÁPS]
INTERFERÃO BETA-1A [6 MUI; 0,5 ML; IM; CANETA] INTERFERÃO BETA-1A [6 MUI; 0,5 ML; IM; CANETA]